Skip to Content
NanomaterialsNanomaterials
  • Correction
  • Open Access

28 February 2024

Correction: Jamal et al. Preparation of 6-Mercaptopurine Loaded Liposomal Formulation for Enhanced Cytotoxic Response in Cancer Cells. Nanomaterials 2022, 12, 4029

,
,
,
,
,
,
and
1
Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia
2
Centre for Artificial Intelligence in Precision Medicines, King Abdulaziz University, Jeddah 21589, Saudi Arabia
3
Division of Biochemistry, Department of Chemistry, Faculty of Science, Tanta University, Tanta 31527, Egypt
4
Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia

Error in Figure

In the original publication [1], there was a mistake in Figures 2 and 3, as published. The confusion occurred during the preparation of the Figures, leading to a mix-up between the control sample and one of the studied samples (Figure 2A,D), and the control sample and one of the studied samples (Figure 3A). The corrected Figure 2 and Figure 3 appear below.
Figure 2. HepG2 staining with Annexin V/7-PI; control (A); treated with 30 µg/mL 6-MP (B); 5 µg/mL 6-MP loaded with positive charge liposome [F1] (C); and free positive charge liposomes [F3] (D).
Figure 3. Cycle arrest of untreated HepG2, control (A); treated with 30 µg/mL 6-MP) (B); 5 µg/mL of 6-MP loaded positive charge liposomes [F1] (C); and drug free positive charge liposomes [F3] (D).

Text Correction

Following the error in Figure 3, there was an error in the original text description. A correction has been made to Section 3. Results and Discussion,
3.4. Cell Cycle Analysis of HepG2 Treated with Free 6-MP and Liposomal Formulation (F1), Paragraph 1:
“When compared to untreated HepG2 cells, which were arrested in sub-G1 (5.2%) phase, G0/G1 phase (29.3%), S phase (18.6%), and G2/M (46.3%), respectively, HepG2 cells treated with 6-MP at a dose of 30 µg/mL showed an increase in sub-G1 (6.7%), G0/G1 phase (37.6%) and in S phase (21.8%) and decreased in G2/M (32.8%) (Figures 3A,B and 4)”.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Jamal, A.; Asseri, A.H.; Ali, E.M.M.; El-Gowily, A.H.; Khan, M.I.; Hosawi, S.; Alsolami, R.; Ahmed, T.A. Preparation of 6-Mercaptopurine Loaded Liposomal Formulation for Enhanced Cytotoxic Response in Cancer Cells. Nanomaterials 2022, 12, 4029. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.